Cite

HARVARD Citation

    Sugawara, T. et al. (2019). Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models. International journal of cancer. 145 (5), pp. 1382-1394. [Online]. 
  
Back to record